Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring and other signs of advanced disease in adults with high-risk compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis…
News
ALAGILLE SYNDROME
NewsUsed in Alagille mice, ASO therapy found to improve liver function
An experimental antisense oligonucleotide (ASO) therapy designed to boost production of the Jagged-1 protein — which is known as Jag1 in mice and JAG1 in…
PBGENE-HBV, Precision BioSciences’ experimental gene-editing therapy for chronic hepatitis B, showed antiviral activity across three doses, with the highest dose approaching the benchmark…
CHOLANGITIS
NewsLivdelzi maintains benefits for up to 3 years in PBC: Phase 3 data
Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers of liver injury in adults…
FATTY LIVER DISEASE
NewsNew drug HU6 cuts liver fat but preserves muscle mass
HU6, an experimental oral therapy from Rivus Pharmaceuticals, safely and effectively reduced liver fat and led to fat-selective weight loss in adults with metabolic…
BILIARY ATRESIA
NewsBetter to have Kasai surgery before liver transplant for biliary atresia
For infants with biliary atresia, undergoing standard Kasai surgery — a procedure to restore the flow of the digestive fluid bile in the body…
Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and elebsiran in people with chronic…
The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…
CHOLESTASIS
NewsNovel gene mutation is likely cause of newborn’s rare liver disease
A novel mutation in the NR1H4Â gene was the likely cause of progressive familial intrahepatic cholestasis (PFIC) type 5 in a baby girl in Tunisia,…
FATTY LIVER DISEASE
NewsEmerging forever chemical may drive fatty liver disease
Exposure to a human-made chemical called perfluoroheptanoic acid (PFHpA) may increase the risk and severity of fatty liver disease in adolescents with obesity, according…
Recent Posts
- Putting out the fires of inflammation in liver disease
- Change is good, but in life with MASH, it’s important to start small
- It turns out that having great friends is good for my health
- With Alagille syndrome, summer fun comes with a summer caution
- Gene therapy shows early promise for fatal childhood liver disease